Clinical Trials Directory

Trials / Unknown

UnknownNCT05772091

Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach

Valeur Pronostique Dans Une Population d'Amylose Cardiaque Des paramètres échocardiographiques basée Sur Une Approche d'Apprentissage Automatique

Status
Unknown
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
Pr. Nicolas GIRERD · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved ejection fraction. Its diagnosis is currently based on a non-invasive method including biology and imaging. Still currently incurable, the evolution of this pathology is burdened by numerous comorbidities, including iterative hospitalizations for heart failure leading to death. The Machine Learning approach has already shown its efficiency in terms of diagnosis but its prognostic approach has not yet been studied.

Conditions

Timeline

Start date
2023-09-29
Primary completion
2024-03-31
Completion
2024-03-31
First posted
2023-03-16
Last updated
2024-03-28

Locations

4 sites across 1 country: France

Source: ClinicalTrials.gov record NCT05772091. Inclusion in this directory is not an endorsement.